Avantor downgraded by Goldman with a new price target
$AVTR
Biotechnology: Laboratory Analytical Instruments
Industrials
Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $14.00 | Buy → Neutral | Goldman |
| 4/28/2025 | $15.50 | Buy → Hold | TD Cowen |
| 4/28/2025 | $14.00 | Buy → Hold | Stifel |
| 4/28/2025 | Overweight → Equal-Weight | Morgan Stanley | |
| 1/17/2025 | $29.00 → $25.00 | Buy → Neutral | UBS |
| 8/28/2024 | $30.00 | Overweight | Wells Fargo |
| 7/10/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $19.50 → $26.00 | In-line → Outperform | Evercore ISI |
RADNOR, Pa., May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m. Eastern Time. To view the presentation slides and to hear a live audio webcast of the session, visit Events & Presentations in the I
RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience
Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led